CHD
Catalysts
Key Risks
The Opportunity
Church & Dwight is the company behind Arm & Hammer baking soda, OxiClean, TheraBreath mouthwash, Hero pimple patches, and Trojan condoms. It's a collection of strong consumer brands that people buy repeatedly - laundry detergent, toothpaste, cat litter, deodorant. These are not exciting products, but that's the point: people keep buying them regardless of what the economy is doing. The company makes about $6.2 billion in annual revenue and converts over $1 billion of that into free cash.
The question for investors is not whether Church & Dwight is a good business - it clearly is. The question is whether the stock price already reflects that quality. At roughly $99 per share, you're paying about 31 times last year's earnings and 24 times next year's expected earnings. That's a hefty price tag. To justify it, you need to believe the company can keep growing earnings at 7% or more for many years. That's doable but not assured, especially since revenue is only growing at 1-2% organically and the rest comes from cost efficiencies and buying other brands.
What could go right: TheraBreath is the company's most exciting growth engine, operating in a massive $47 billion oral care market where it still has tiny market share. Recent acquisitions like Miss Mouth's (the top stain remover on Amazon) and Touchland (premium hand sanitizer) could scale significantly through Church & Dwight's retail distribution network. The company also demonstrated smart risk management by cutting its tariff exposure from $190 million down to about $25 million through supply chain changes.
The main thing that could go wrong: Church & Dwight is increasingly reliant on buying brands to grow. It spent over $1.2 billion on acquisitions in the past year alone, and not every deal works out - it had to write down and sell off its vitamin brands after they underperformed. If one or two of the newer acquisitions stumble, it would hurt both earnings and investor confidence in the strategy. Meanwhile, store-brand alternatives are slowly gaining ground, especially with younger shoppers who are less loyal to name brands.
At today's price, our analysis suggests the stock is about 12% above fair value. It's a high-quality company priced for near-perfection, which leaves limited margin for error. Patient investors might find a better entry point during a market pullback, but this is not a stock to avoid entirely - it's simply one where the price has gotten ahead of the fundamentals.
How we got to $72 - $100
Breakdown
Church & Dwight's balance sheet as of Q2 2026 shows $9.11B in total assets against $4.76B in total liabilities, yielding $4.35B in book equity ($17.67/share). The company trades at 5.38x book, which is typical for an asset-light consumer staples business whose value resides in brands rather than hard assets. The key balance sheet consideration is the intangible asset base - trade names, customer relationships, and goodwill from acquisitions of TheraBreath ($580-690M range, 2021), Hero (~$630M, 2022), Touchland (~$880M total, 2025), and Miss Mouth's ($325M, 2026) [BusinessWire, May 2026].
These acquisitions have loaded the balance sheet with goodwill and intangibles that likely constitute roughly half of total assets. The fair value of these intangibles is debatable: TheraBreath and Hero appear to be performing well (TheraBreath is cited as the fastest-growing tracked brand), but the VMS (VitaFusion/L'il Critters) business was written down and divested in December 2025 [BusinessWire, December 2025], and Spinbrush and Flawless trade names also show impairment charges in the 10-Q filings. This suggests some acquisition track record erosion, though the core brand portfolio remains strong.
Long-term debt of $2.21B is well-structured across multiple senior note tranches: 3.15% due 2027, 2.3% due 2031, 5.6% due 2032, 3.95% due 2047, and 5.0% due 2052 - a well-laddered maturity profile with no near-term refinancing risk. Debt/equity at 0.52 is conservative for the sector. Cash of $254.8M provides adequate but not excessive liquidity, down from $964.1M at year-end 2024, reflecting the Touchland and Miss Mouth's acquisition spend.
The current ratio of 1.15 and quick ratio of 0.69 are adequate for a consumer staples company with predictable cash flows, though the quick ratio flags modest working capital tightness. Net asset value at $18.35/share represents a floor that is essentially irrelevant - this is a going-concern brand portfolio, not a liquidation candidate.
Church & Dwight generated $1.115B in free cash flow over the trailing twelve months, translating to a 4.76% FCF yield at the current $23.4B market cap and $4.71 FCF per share. Capital allocation follows a clear playbook: (1) bolt-on acquisitions of high-growth niche brands (Touchland, Miss Mouth's, Hero, TheraBreath), (2) dividends ($1.22/share annualized, 1.23% yield, 39% payout ratio - conservatively covered and growing), (3) share buybacks (share count has been relatively stable around 237M, suggesting modest net buybacks after stock-based compensation), and (4) debt maintenance. The dividend has been increased consistently for over 25 years, making CHD a Dividend Aristocrat.
The 39% payout ratio leaves significant room for both dividend growth and reinvestment. The acquisition strategy is the most consequential capital allocation decision: approximately $1.2B+ deployed on Touchland and Miss Mouth's in 2025-2026 alone. The Miss Mouth's deal at ~$325M for ~$80M revenue and ~$28M EBITDA implies roughly 11.6x EV/EBITDA and 4.1x revenue - premium multiples that demand strong execution [BusinessWire, May 2026].
The VMS divestiture signals management willingness to prune underperformers rather than throwing good money after bad, which is a positive governance signal. The concern is that the acquisition pace is accelerating and the company is paying growth-company multiples for these bolt-ons, which raises execution risk. Stock-based compensation appears modest based on insider transaction data showing small periodic awards to executives.
CHD's financial track record over 2016-2025 is impressive in its consistency. Revenue grew from $3.49B (2016) to $6.20B (2025), a 6.6% CAGR. Gross margins expanded from 45.6% (2016) to 44.7% in the 2025 reported year, though they dipped to 41.8% in 2022 during the inflationary squeeze before recovering.
The most recent quarters show gross margins at 45.4-46.4%, at or above pre-COVID levels. Operating income has been less consistent: the 2022 operating margin compressed to 11.1% ($597.8M on $5.38B revenue) before recovering to 17.5% by 2025, reflecting the transitory impact of commodity inflation. EPS tells a similar story: $1.75 (2016) to $3.02 (2025), but with a notable trough at $1.68 in 2022 and an aberrant $2.37 in 2024 (which included a Q3 2024 loss of -$0.31/share, likely from impairment charges related to VMS).
Stripping out the one-time items, the underlying earnings power has grown steadily. On earnings calls, CHD has beaten EPS estimates in 6 of the last 7 reported quarters - Q4 2024 beat by $0.11, Q3 2025 beat by $0.08, Q4 2025 beat by $0.07, Q1 2026 beat by $0.02, Q2 2026 beat by $0.02. The only miss was Q1 2025 which met estimates exactly. This consistency reflects disciplined guidance-setting, which is a management quality indicator.
The organic growth of 5-5.8% in recent quarters outpaces the 3% initial guidance, driven by volume rather than price - a healthier mix that suggests genuine consumer demand rather than inflation pass-through.
Consensus estimates project 7.1% EPS growth over the next 5 years, with near-term estimates of 6.4% this year and 7.2% next year. The reverse-DCF implies the market prices in 5.9% growth - slightly below the analyst consensus, which suggests the market is not being overly optimistic. However, the stock's 31.4x trailing P/E and 24.1x forward P/E embed substantial premium for quality and consistency.
At $4.09 forward EPS and 7% growth, a PEG of 3.4x is rich by any standard - even for a consumer staples compounder, PEG ratios above 2.5x historically signal limited upside. The growth drivers are identifiable: (1) TheraBreath expanding in the $47B oral care market from a small base [Koala Gains, 2026], (2) digital-first brand acquisitions (Touchland, Miss Mouth's) leveraging CHD's retail distribution, (3) new product launches expected to drive ~50% of 2026 organic growth [Church & Dwight Q1 2026 Investor Release, May 2026], and (4) international expansion (currently ~20% of sales). Management raised 2026 guidance to flat-to-+1% net sales growth and 6-8% adjusted EPS growth [Benzinga, July 2026].
Tariff exposure was mitigated from $190M to $25-28M through supply chain restructuring [Alphastreet, 2026], which is a meaningful positive. The key risk to forward growth is that CHD is increasingly dependent on M&A-driven growth as organic top-line expansion stays in the low-to-mid single digits. The 7% earnings growth rate is achievable through margin expansion and buybacks even with modest revenue growth, but sustaining it beyond 3-5 years requires continued successful acquisitions.
Church & Dwight possesses a narrow-to-wide moat built on several reinforcing factors. Brand recognition is the primary moat source: Arm & Hammer (the world's leading baking soda brand) has been in use for over 170 years, creating deep consumer trust that extends across laundry, oral care, cat litter, and personal care categories. The power brand strategy - where approximately 70% of revenue comes from a handful of dominant brands including Arm & Hammer, OxiClean, TheraBreath, Hero, Batiste, and Vitafusion - creates marketing efficiency and retail shelf space leverage.
Switching costs are moderate: consumers develop product loyalty in categories like oral care (TheraBreath) and laundry (Arm & Hammer) but could switch to competitors or private label without friction. Distribution scale provides a cost advantage: CHD's ability to place products across Walmart (a major customer per concentration risk disclosures), Amazon, and mass retail channels is difficult for smaller competitors to replicate. The acquisition of digital-native brands (Hero, Touchland, Miss Mouth's - the #1 stain remover on Amazon [BusinessWire, May 2026]) extends the moat into e-commerce channels.
The moat trend is stable-to-strengthening in oral care and personal care (where TheraBreath and Hero are gaining share), but faces structural pressure in laundry and household categories from private label encroachment - store brand unit sales grew 0.3% while national brands declined 0.7% [Numerator, 2025]. The moat width is best described as narrow with potential to widen: CHD lacks the sheer scale advantages of P&G but compensates with category leadership in profitable niches.
The CEO transition from Matt Farrell (who doubled market cap to over $25B during his tenure) to Rick Dierker effective April 2025 is the most important governance event [BusinessWire, September 2024]. Dierker is a 15-year CHD veteran who served as CFO and Head of Business Operations, providing deep institutional knowledge. His compensation ($1.075M base, 125% target bonus, $7.08M LTI) is aligned with performance without being excessive [Panabee, 2025].
The most material governance concern is the SEC enforcement action against former CEO/director James Craigie, who was charged with concealing a personal friendship with a senior executive, resulting in a $175,000 penalty and 5-year officer/director bar [SEC.gov, October 2024]. While the financial impact is negligible, it raises questions about board independence and oversight culture [Foley & Lardner, December 2024]. Insider ownership at 0.24% is low, which is typical for large-cap consumer staples but does not provide strong alignment.
Net insider transactions show -10.63% (net selling), with the notable transaction being EVP Linares selling 10,000 shares at ~$100 in June 2026. Director stock awards are small routine grants. Institutional ownership at 94% with Vanguard (~13%), BlackRock (~8.8%), and State Street (~5.3%) dominating [Yahoo Finance, 2025] provides stability but also means the stock is priced by sophisticated investors with limited information asymmetry.
The willingness to divest underperforming brands (VMS, Flawless, Spinbrush, Waterpik showerheads) while acquiring in higher-growth categories demonstrates rational capital allocation - the hallmark of competent management.
The risk profile is moderate for a consumer staples company. Key risks include: (1) Customer concentration: Walmart and its affiliates represent a significant portion of revenue, creating negotiating leverage risk and channel dependency. (2) Acquisition integration risk: CHD has deployed over $1.5B in M&A over the past two years (Touchland ~$880M, Miss Mouth's $325M), and the VMS write-down demonstrates that not every acquisition works. The Touchland deal includes up to $159M in contingent payments, adding financial complexity. (3) Legal exposure: Multiple active class actions covering Trojan PFAS allegations, L'il Critters marketing claims, Arm & Hammer detergent fill levels, and Zicam contamination [ClassAction.org, 2024-2025].
While individually immaterial, the cumulative pattern suggests product liability risk across the portfolio. (4) Private label competition: Store brand penetration is increasing, particularly among Gen Z and Millennial consumers [Numerator, 2025], creating structural pricing pressure in household categories. (5) Tariff and input cost volatility: While CHD has mitigated near-term tariff exposure from $190M to $25-28M [Alphastreet, 2026], further trade policy changes could reignite cost pressures. (6) Currency risk: ~20% of revenue is international, creating FX translation exposure. (7) Valuation risk: At 31x trailing earnings, any disappointment in growth delivery could trigger multiple compression - the stock's premium pricing leaves little room for error. The short float at 4.31% with 5.09 days to cover suggests mild bearish positioning but nothing alarming.
The soap, detergent, and personal care sector provides a growing backdrop: the global market is valued at ~$159B growing at ~6% CAGR [Research and Markets, 2026]. CHD occupies a strong position as a mid-sized player competing against giants (P&G, Unilever, Colgate-Palmolive) through category specialization rather than broad-line competition. The company holds #1 or #2 positions in most of its key categories, which provides pricing power and distribution advantages.
Industry sentiment is favorable for defensive names: the news sentiment data shows predominantly positive coverage, with CHD frequently cited as a recommended holding in uncertain market environments [Motley Fool, June 2025]. Analyst consensus at 2.27 (between buy and hold, skewing buy) with a $104.39 target price suggests moderate upside expectations. The laundry detergent market is projected to reach $131B by 2035 at 5.2% CAGR [SNS Insider, 2026], and the dry shampoo market (relevant for Batiste) is growing at 4.3% CAGR to $5.37B by 2030 [MarketsandMarkets, 2026].
TheraBreath's position in the $47B oral care market offers the largest expansion runway. M&A activity positions CHD as an active acquirer rather than a target - the dominant passive institutional ownership base makes activist intervention unlikely [Yahoo Finance, 2025]. Social sentiment averaging 5.3/10 across platforms suggests neutral-to-mildly-positive retail investor sentiment.
The stock's 0.47 beta confirms its role as a defensive holding, which attracts capital during periods of market uncertainty.